Anavex Life Sciences Corp (AVXL)

[Investor2014]

Annovis straight up recognises that a pivotal PIII trial is required!

Based on the findings of this symptomatic study, Annovis plans to conduct a pivotal disease-modifying Phase III trial in biomarker-positive early AD patients

Of course the Anavex P2b/3 trial wasn't stat sig on the ADL co-primary endpoint, but according to some has an 85% chance of EMA approval. Anavex will as is typical wait for the15% scenario to play out before soon'ish after finally recognising a P3 confirmatory trial is needed.

Anavex actually originally recognised that a confirmatory trial would be needed, but that was until Missling overheard someone saying that the OLE data could make up for a confirmatory trial. One wonders why all that was even necessary given that "all endpoints were met"?

Oh well, pennywise and pound foolish is the Missling name of the game.